Home » Clinical Trials » Leukemia » NCT04532268
NCT04532268

Clinical Trial for the Safety and Efficacy of Humanized CD19 CAR-T Cells Therapy for Patients With Relapsed and/or Refractory B-cell Acute Lymphoblastic Leukemia and B-cell Non-Hodgkin's Lymphoma

Study Summary

A Study of Humanized CD19 CAR-T Cells Therapy for Patients With Relapsed and/or Refractory B-cell Acute Lymphoblastic Leukemia and B-cell Non-Hodgkin's Lymphoma.

Interested in this trial?

Submit an Inquiry

Interventions

Humanized CD19 CAR-T cellsDRUG
Each subject receive humanized CD19 CAR T-cells by intravenous infusion

Study Locations

FacilityCityStateCountry
The First Affiliated Hospital，College of Medicine, Zhejiang UniversityHangzhouZhejiangChina

Official Trial Information

View on ClinicalTrials.gov

Data sourced from ClinicalTrials.gov. Last updated: May 29, 2026